| 1 |
Fakhouri F, Frémeaux-Bacchi V, Noël LH, et al. C3 glomerulopathy: a new classification [J]. Nat Rev Nephrol, 2010, 6(1): 494-499.
|
| 2 |
Verroust PJ, Wilson CB, Cooper NR, et al. Glomerular complement components in human glomerulonephritis [J]. J Clin Invest, 1974, 53(1): 77-84.
|
| 3 |
喻小娟，刘刚，赵明辉. 12例C3肾小球肾炎的临床病理特点及其血浆补体活化分析[J]. 中华肾脏病杂志，2011, 27(11): 797-801.
|
| 4 |
Servais A, Frémeaux-Bacchi V, Lequintrec M, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome [J]. J Med Genet, 2007, 44(3): 193-199.
|
| 5 |
Servais A, Noël LH, Roumenina LT, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies [J]. Kidney Int, 2012, 82(4): 454-464.
|
| 6 |
Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis [J]. Lancet, 2010, 376(9743): 794-801.
|
| 7 |
章海涛，陈惠萍，曾彩虹，等. C3肾小球肾炎的临床表现及病理特[J]. 肾脏病与透析肾移植杂志，2011，20(4): 307-311，337.
|
| 8 |
Appel GB, Cook HT, Hageman G, et al. Membranoproliferative glomerulonephritis type II (dense deposit disease): an update [J]. J Am Soc Nephrol, 2005, 16(5): 1392-1403.
|
| 9 |
Spitzer RE, Vallota EH, Forristal J, et al. Serum C′3 lytic system in patients with glomerulonephritis [J]. Science, 1969, 164(3878): 436-437.
|
| 10 |
Zhang Y, Meyer NC, Wang K, et al. Causes of alternative pathway dysregulation in dense deposit disease [J]. Clin J Am Soc Nephrol, 2012, 7(2): 265-274.
|
| 11 |
Paixão-Cavalcante D, López-Trascasa M, Skattum L, et al. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation [J]. Kidney Int, 2012, 82(10): 1084-1092.
|
| 12 |
Nasr SH, Valeri AM, Appel GB, et al. Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients [J]. Clin J Am Soc Nephrol, 2009, 4(1): 22-32.
|
| 13 |
Goodship TH, Pappworth IY, Toth T, et al. Factor H autoantibodies in membranoproliferative glomerulonephritis [J]. Mol Immunol, 2012, 52(3-4): 200-206.
|
| 14 |
Strobel S, Zimmering M, Papp K, et al. Anti-factor B autoantibody in dense deposit disease [J]. Mol Immunol, 2010, 47(7-8): 1476-1483.
|
| 15 |
Chen Q, Müller D, Rudolph B, et al. Combined C3b and factor B autoantibodies and MPGN type II [J]. N Engl J Med, 2011, 365(24): 2340-2342.
|
| 16 |
Martínez-Barricarte R, Heurich M, Valdes-Caedo F, et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation [J]. J Clin Invest, 2010, 120(10): 3702-3712.
|
| 17 |
Bomback AS, Smith RJ, Barile GR, et al. Eculizumab for dense deposit disease and C3 glomerulonephritis [J]. Clin J Am Soc Nephrol, 2012, 7(5): 748-756.
|
| 18 |
Habbig S, Mihatsch MJ, Heinen S, et al. C3 deposition glomerulopathy due to a functional factor H defect [J]. Kidney Int, 2009, 75(11): 1230-1234.
|
| 19 |
Schejbel L, Schmidt IM, Kirchhoff M, et al. Complement factor H deficiency and endocapillary glomerulonephritis due to paternal isodisomy and a novel factor H mutation [J]. Genes Immune, 2011, 12(2): 90-99.
|
| 20 |
Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis [J]. Lancet, 2010, 376(9743): 794-801.
|
| 21 |
Servais A, Noёl LH, Frémeaux-Bacchi V, et al. C3 glomerulopathy [J]. Contrib Nephrol, 2013, 181: 185-193.
|
| 22 |
Sethi S, Fervenza FC, Zhang Y, et al. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement [J]. Clin J Am Soc Nephrol, 2011, 6(5): 1009-1017.
|
| 23 |
Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN [J]. J Am Soc Nephrol, 2012, 23(7): 1229-1237.
|
| 24 |
Keating GM. Eculizumab: a review of its use in atypical haemolytic uraemic syndrome [J]. Drugs, 2013, 73(18): 2053-2066.
|
| 25 |
Nester CM, Brophy PD. Eculizumab in the treatment of atypical haemolytic uraemic syndrome and other complement-mediated renal diseases [J]. Curr Opin Pediatr, 2013, 25(2): 225-231.
|
| 26 |
Vivarelli M, Emma F. Treatment of C3 glomerulopathy with complement blockers [J]. Semin Thromb Hemost, 2014, 40(4): 472-477.
|
| 27 |
Gurkan S, Fyfe B, Weiss L, et al. Eculizumab and recurrent C3 glomerulonephritis [J]. Pediatr Nephrol, 2013, 28(10): 1975-1981.
|
| 28 |
Zhang Y, Nester CM, Holanda DG, et al. Soluble CR1 therapy improves complement regulation in C3 glomerulopathy [J]. J Am Soc Nephrol, 2013, 24(11): 1820-1829.
|
| 29 |
Hong Y, Zhou W, Li K, et al. Triptolide is a potent suppressant of C3, CD40 and B7h expression in activated human proximal tubular epithelial cells [J]. Kidney Int, 2002, 62(4): 1291-1300.
|
| 30 |
Wang J, Tang Z, Luo C, et al. Clinical and pathological features of dense deposit disease in Chinese patients [J]. Clin Nephrol, 2012, 78(3): 207-215.
|
| 31 |
牛延峰. 五苓散加减佐治系膜增生性肾小球肾炎43例观察[J]. 国医论坛，2014, 29(5): 31-32.
|
| 32 |
王亿平，唐锦囊，王东，等. 参地颗粒对系膜增生性肾小球肾炎大鼠血清和肾脏M M P-9/T IM P-1的影响[J]. 安徽中医药大学学报，2014，33(5): 78-81.
|
| 33 |
蒋文功，杨乐鹏，谢谦，等. 骨碎补总黄酮对系膜增生性肾小球肾炎大鼠血清白血病介素-6的影响[J]. 中国中西医结合肾病杂志，2014，15(6): 484-486.
|
| 34 |
毋建华. 氯沙坦联合金水宝治疗系膜增生性肾小球肾炎疗效观察[J]. 山西职工医学院学报，2014，24(1): 23-25.
|
| 35 |
Barbour TD, Pickering MC, Cook HT. Recent insights into C3 glomerulopathy [J]. Nephrol Dial Transplant, 2013, 28(7): 1685-1693.
|
| 36 |
Licht C, Heinen S, Józsi M, et al. Deletion of Lys224 in regulatory domain 4 of Factor H reveals a novel pathomechanism for dense deposit disease (MPGN II) [J]. Kidney Int, 2006, 70(1): 42-50.
|